UA108852C2 - Применение одного или комбинации фито каннабиноидов для лечения эпилепсии - Google Patents

Применение одного или комбинации фито каннабиноидов для лечения эпилепсии

Info

Publication number
UA108852C2
UA108852C2 UAA201201092A UAA201201092A UA108852C2 UA 108852 C2 UA108852 C2 UA 108852C2 UA A201201092 A UAA201201092 A UA A201201092A UA A201201092 A UAA201201092 A UA A201201092A UA 108852 C2 UA108852 C2 UA 108852C2
Authority
UA
Ukraine
Prior art keywords
treatment
epilepsy
combination
phytocanabinoids
application
Prior art date
Application number
UAA201201092A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Бен Уеллі
Гері Стефенс
Клер Уілльямс
Джеффрі Гай
Стефен Райт
Тецуро Кікуті
Original Assignee
Джидаблю Фарма Лімітед
Оцука Фармасьютікал Ко. Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41008705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA108852(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джидаблю Фарма Лімітед, Оцука Фармасьютікал Ко. Лімітед filed Critical Джидаблю Фарма Лімітед
Publication of UA108852C2 publication Critical patent/UA108852C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
UAA201201092A 2009-07-03 2010-06-29 Применение одного или комбинации фито каннабиноидов для лечения эпилепсии UA108852C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0911580A GB2471523A (en) 2009-07-03 2009-07-03 Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
PCT/GB2010/051066 WO2011001169A1 (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy

Publications (1)

Publication Number Publication Date
UA108852C2 true UA108852C2 (ru) 2015-06-25

Family

ID=41008705

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201201092A UA108852C2 (ru) 2009-07-03 2010-06-29 Применение одного или комбинации фито каннабиноидов для лечения эпилепсии

Country Status (28)

Country Link
US (4) US9066920B2 (enExample)
EP (3) EP2727626A1 (enExample)
JP (2) JP5904938B2 (enExample)
KR (1) KR101727000B1 (enExample)
CN (2) CN102596322A (enExample)
AR (1) AR077448A1 (enExample)
AU (1) AU2010267775C1 (enExample)
BR (1) BR112012000076A2 (enExample)
CA (2) CA3040410C (enExample)
CY (1) CY1115338T1 (enExample)
DK (1) DK2448637T4 (enExample)
ES (1) ES2460623T5 (enExample)
GB (3) GB2471523A (enExample)
HR (1) HRP20140398T4 (enExample)
IL (1) IL217280B (enExample)
IN (1) IN2012DN00804A (enExample)
MX (1) MX2012000257A (enExample)
MY (1) MY156759A (enExample)
NZ (2) NZ597704A (enExample)
PL (1) PL2448637T5 (enExample)
PT (1) PT2448637E (enExample)
RU (1) RU2563143C2 (enExample)
SG (1) SG176914A1 (enExample)
SI (1) SI2448637T2 (enExample)
TW (1) TWI461191B (enExample)
UA (1) UA108852C2 (enExample)
WO (1) WO2011001169A1 (enExample)
ZA (1) ZA201200373B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
EP1811983B1 (en) * 2004-11-16 2020-10-07 GW Pharma Limited New use for cannabinoid
US11062795B2 (en) 2007-03-02 2021-07-13 Enigami Systems, Inc. Healthcare data system
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2479153B (en) * 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) * 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US10319475B1 (en) 2014-06-13 2019-06-11 Enigami Systems, Inc. Method and apparatus for determining relationships between medications and symptoms
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
WO2016044370A1 (en) 2014-09-16 2016-03-24 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
WO2016118391A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
AU2016211314A1 (en) 2015-01-31 2017-08-17 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
WO2016160542A1 (en) * 2015-04-01 2016-10-06 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2016176279A1 (en) * 2015-04-28 2016-11-03 The Regents Of The University Of California Uses of cannabidiol for treatment of infantile spasms
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2017027651A1 (en) 2015-08-12 2017-02-16 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
US10806707B2 (en) 2015-11-24 2020-10-20 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
US10143706B2 (en) 2016-06-29 2018-12-04 Cannscience Innovations, Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN108236608B (zh) * 2016-12-27 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
CN108245499B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途
CN108245510B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
CN108245517B (zh) * 2016-12-29 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与拉莫三嗪的药物组合物及其用途
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
CN108785298A (zh) * 2017-04-27 2018-11-13 汉义生物科技（北京）有限公司 一种用于治疗癫痫的药物组合物、其制备方法及用途
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB2583526A (en) 2019-05-03 2020-11-04 Gw Res Ltd Use of cannabidiol in the treatment of tuberous sclerosis complex
CN110101804A (zh) * 2019-05-30 2019-08-09 厦门梓素生物科技有限公司 一种含大麻二酚提取物的癫痫药物组合及其制备方法
US20210077421A1 (en) * 2019-09-17 2021-03-18 Zynerba Pharmaceuticals, Inc. Treatment of syngap1 encephalopathy
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
EP3912485A1 (en) 2020-05-18 2021-11-24 Del-Vis Sp. z o.o. Cigarette product and a method for manufacturing the product
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597279A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
CA3187303A1 (en) 2020-07-28 2022-02-03 Impello Biosciences, Inc. Methods and compositions for altering secondary metabolites in plants
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
GB2604132A (en) 2021-02-25 2022-08-31 Gw Res Ltd Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes
US11337934B1 (en) 2021-04-08 2022-05-24 Lanny Leo Johnson Compositions including a cannabinoid and protocatechuic acid
CN118510544A (zh) 2021-07-29 2024-08-16 爱莫里大学 大麻素类的磷酸酯前药
CA3248533A1 (en) 2022-04-12 2023-10-19 Shackelford Pharma Inc TREATMENT OF EPILEPTIC DISORDERS

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
JP4467883B2 (ja) 2001-02-14 2010-05-26 ジーダブリュー・ファーマ・リミテッド 医薬製剤
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
ITPD20020138A1 (it) 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
CA2823474A1 (en) 2002-08-14 2004-02-14 Gw Pharma Limited Botanical drug substances comprising various proportions of thc and cbd
AU2003253005B2 (en) * 2002-08-14 2009-03-19 Jazz Pharmaceuticals Research Uk Limited Cannabinoid liquid formulations for mucosal administration
EP1811983B1 (en) * 2004-11-16 2020-10-07 GW Pharma Limited New use for cannabinoid
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
WO2007142957A2 (en) 2006-05-30 2007-12-13 Air Systems Gear drive damper
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
PT2280687T (pt) 2008-03-26 2019-06-04 Stichting Sanammad Composições de goma de mascar compreendendo canabinóides
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
CA2847235C (en) 2011-08-26 2020-07-07 Bial - Portela & Ca, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US20150181924A1 (en) 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
US10052339B2 (en) 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
CA2950424C (en) 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
ZA201200373B (en) 2012-09-26
EP2448637A1 (en) 2012-05-09
US9066920B2 (en) 2015-06-30
HRP20140398T1 (hr) 2014-06-20
CA2766082C (en) 2019-06-11
IL217280A0 (en) 2012-02-29
JP2012532093A (ja) 2012-12-13
IN2012DN00804A (enExample) 2015-06-26
US20190247324A1 (en) 2019-08-15
AU2010267775A1 (en) 2012-02-23
US20150335590A1 (en) 2015-11-26
JP2016166205A (ja) 2016-09-15
CN102596322A (zh) 2012-07-18
EP2448637B2 (en) 2022-06-08
US20170273913A1 (en) 2017-09-28
MX2012000257A (es) 2012-01-27
US9522123B2 (en) 2016-12-20
CA3040410A1 (en) 2011-01-06
CA2766082A1 (en) 2011-01-06
KR101727000B1 (ko) 2017-05-02
PT2448637E (pt) 2014-05-27
KR20120088648A (ko) 2012-08-08
GB2471565A (en) 2011-01-05
SI2448637T2 (sl) 2022-10-28
NZ620838A (en) 2015-08-28
AU2010267775B2 (en) 2016-10-06
GB2471565B (en) 2012-07-04
GB201010897D0 (en) 2010-08-11
NZ597704A (en) 2014-05-30
GB0911580D0 (en) 2009-08-12
BR112012000076A2 (pt) 2020-06-02
HK1164766A1 (en) 2012-09-28
DK2448637T4 (da) 2022-09-12
RU2563143C2 (ru) 2015-09-20
IL217280B (en) 2018-05-31
CN106236744A (zh) 2016-12-21
GB2485291A (en) 2012-05-09
ES2460623T3 (es) 2014-05-14
AU2010267775C1 (en) 2020-02-27
TWI461191B (zh) 2014-11-21
GB2471523A (en) 2011-01-05
WO2011001169A1 (en) 2011-01-06
MY156759A (en) 2016-03-31
DK2448637T3 (da) 2014-05-26
EP3718603A1 (en) 2020-10-07
GB201121919D0 (en) 2012-02-01
JP5904938B2 (ja) 2016-04-20
HRP20140398T4 (hr) 2022-10-14
EP2448637B1 (en) 2014-03-12
PL2448637T3 (pl) 2014-08-29
TW201105318A (en) 2011-02-16
CA3040410C (en) 2023-03-28
RU2012103603A (ru) 2013-08-10
PL2448637T5 (pl) 2022-10-03
AR077448A1 (es) 2011-08-31
CY1115338T1 (el) 2017-01-04
SI2448637T1 (sl) 2014-07-31
EP2727626A1 (en) 2014-05-07
US20120165402A1 (en) 2012-06-28
GB2485291B (en) 2013-03-27
ES2460623T5 (es) 2022-10-14
SG176914A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
UA108852C2 (ru) Применение одного или комбинации фито каннабиноидов для лечения эпилепсии
EA201391733A1 (ru) Каннабиноиды, применяемые для лечения невропатической боли
MX2021010033A (es) Composiciones microencapsuladas de cannabinoides.
MX356282B (es) Composiciones y metodos que comprenden variantes de proteasa.
UY33735A (es) Compuestos antivirales
EA201290975A1 (ru) Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии
GEP20146003B (en) Benzothiazole derivatives as anticancer agents
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
MX2010005114A (es) Uso de las soluciones de aceite de menta o de l-carvona para el tratamiento fungicida y/o antigerminacion de bulbos y/o tuberculos.
CR20120204A (es) Nuevo uso antitumoral de cabazitaxel
BR112012000718A2 (pt) concentrado para produção de um agente de refrigeração e de separação ou de um agente de refrigeração e de lubrificação, bem como o agente de refrigeração e de separação e agente de refrigeração e de lubrificação desse tipo
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
CL2012000316A1 (es) Compuestos fungicidas derivados de n1-acil-5-fluoro-pirimidinona; composiciones que los comprenden y metodo que los emplea para combatir hongos fitopatogenos.
BR112013012571A2 (pt) composições fungicidas e métodos
MX2011012741A (es) Un suplemento que comprende grosellas negras o moras grandes.
BRPI0812022A2 (pt) Composições para produção de soja com teor de óleo elevado.
MX2010007810A (es) Coposicion que contiene capsicum para tratar un trastorno de la piel.
EA201290622A1 (ru) Способ выбора бактерий с антиоксидантным действием
CL2012001071A1 (es) Compuesto derivado de n-bencilformamida o n-benciltioformamida; composicion fungicida que la comprende; metodo para controlar patogenos fungicos en plantas.
ECSP12011996A (es) Moduladores de crth2
WO2011029536A3 (de) Verwendung von cyclischen ketoenolen gegen pflanzenpathogene bakterien
BRPI1015432A8 (pt) Composição e método para melhorar a saúde vascular
TH153696A (th) การใช้ไฟโตแคนนาบินอยด์หรือสารผสมของสารดังกล่าวในการรักษาโรคลมบ้าหมู
UA77064U (ru) Ректальный суппозиторий от геморроя "ректолик"
EA201690140A1 (ru) Получение хиральных 4-хроманонов с применением хиральных пирролидинов в присутствии фенолов или тиофенолов